Information on Q1 2018 Financial Results Q1 2018 Change Change at Constant Exchange Rates Net sales reported 7,898m -8.7 % -0.4 % Net income reported 1,016m -82.2 % ( 1 ) Earnings per Share reported 0.81 -82.0 % ( 2 ) Bu

Information on Q1 2018 Financial Results

2018 first-quarter Sanofi sales

In the first quarter of 2018, Company sales were 7,898 million, down 8.7% on a reported basis. Exchange rate movements had a negative effect of 8.3

percentage points mainly driven by the movement of the U.S. Dollar accompanied by the Brazilian Real, Chinese Yuan, Japanese Yen and Argentine Peso. At CER, Company sales decreased slightly (down 0.4%).

Global Business Units

The table below presents sales by Global Business Unit (GBU). Please note that Emerging Markets sales for Specialty Care and Diabetes and Cardiovascular are

included in the General Medicines and Emerging Markets GBU.

The tables below present first-quarter

2018 sales by global franchise, including Emerging Markets sales, to facilitate comparisons. Appendix 1 provides a reconciliation of sales by GBU and franchise.

First-quarter Pharmaceutical sales were down 9.0% on a reported basis and 0.9% at CER to 5,949 million primarily due to Diabetes and Established Rx

Rare Disease franchise

In the first quarter of 2018, Rare Disease sales increased 6.9% at CER to 695 million, driven by Emerging

Markets (up 20.8% at CER to 129 million) and Europe (up 7.4% at CER to 246 million). In the U.S., first-quarter Rare Disease sales grew 3.3% to 246 million.

First-quarter Gaucher (Cerezyme and

Cerdelga ) sales were up 12.6% at CER to 211 million, supported by the increasing penetration of Cerdelga in the

U.S. and Europe and the sustained growth of Cerezyme in Emerging Markets. First-quarter Cerdelga sales increased 25.8% at CER to

36 million, driven by Europe performance up 100% at CER (to 10 million).

First-quarter Myozyme /Lumizyme sales grew 11.1% at CER to 196 million, supported by positive trends in na ve patient accruals. First-quarter

Myozyme /Lumizyme sales increased 14.6% at CER to 93 million in Europe and 10.4% at CER to 64 million in the

First-quarter Fabrazyme sales grew 6.8% at CER to

170 million. First-quarter sales in the U.S. and Europe increased 6.5% at CER (to 86 million) and 5.0% at CER (to 42 million), respectively.

Multiple Sclerosis franchise

First-quarter Multiple Sclerosis (MS) sales grew 6.5% at CER to 476 million, driven by Aubagio .

First-quarter Aubagio sales increased 11.6% at CER to 371 million, supported by the U.S. (up 13.1% at CER to 254 million) and Europe (up 4.4% at CER to 95 million). In 2017, Sanofi reached settlement

with all 20 generic Aubagio ANDA first filers granting each a royalty-free license to enter the U.S. market on March 12, 2023.

In the first quarter, Lemtrada sales decreased 8.8% at CER to 105 million due to

lower U.S. sales (down 17.9% at CER to 47 million) reflecting increased competition as well as its unique dosing and durable effect. In Europe, Lemtrada sales were up 4.4% at CER to

Immunology franchise

Dupixent (collaboration with Regeneron) was launched in the

U.S. in April 2017 for the treatment of moderate-to-severe atopic dermatitis in adults, in Germany in December 2017 and in the Netherlands, Canada and Denmark during the

first quarter of 2018. Dupixent generated worldwide sales of 107 million in the first quarter, of which 95 million were in the U.S. Underlying demand in the U.S.

remained strong with total prescriptions (source: IQVIA weekly TRx data) growing by 25% compared with the prior quarter. Sales evolution in the U.S. was impacted by trade inventory reduction as well as usual higher contribution to patient assistance

programs in the beginning of the year (combined effect of approximately 30 million).

Kevzara (collaboration with Regeneron) for rheumatoid arthritis was launched in the U.S. in

June 2017 and in Germany, the UK and the Netherlands during the second half of last year. First-quarter Kevzara sales were 10 million, of which 8 million were generated

in the U.S. where commercial coverage of the product reached more than 80% of lives.

Rare Blood Disorder franchise

Sanofi announced the successful completion of its acquisition of Bioverativ, which was consolidated in the Company s

Financial Statements from March 9, 2018. Consolidated sales of the Rare Blood Disorder franchise were 64 million in the first quarter, including non U.S. sales of 13 million with Japan as the primary contributor. Following

the market entry in Colombia in the first quarter of 2018, additional launches in Emerging Markets are expected this year.

Consolidated sales of Eloctate (a recombinant

antihemophilic Factor VIII, Fc Fusion Protein, indicated for the treatment of hemophilia A) were 43 million. Including the sales made by Bioverativ prior to consolidation in Sanofi s results and compared to the first quarter of 2017,

first-quarter Eloctate sales growth was 27% at CER(11).

Consolidated sales of Alprolix (a

recombinant coagulation Factor IX, Fc Fusion Protein, indicated for the treatment of hemophilia B) were 21 million. Including the sales made by Bioverativ prior to consolidation in Sanofi s results and compared to the first quarter

of 2017, first-quarter Alprolix sales growth was 12% at CER(12).

First-quarter oncology sales decreased 5.6% at CER to 358 million. Consistent with the Company s portfolio

prioritization efforts, Sanofi sold Leukine on January 31, 2018. Excluding Leukine , oncology first-quarter sales were up 3.5% at

Jevtana sales were up 10.3% at

CER to 99 million in the first quarter supported by the performance in the U.S. (up 17.5% at CER to 41 million). In the first quarter, Thymoglobulin and

Eloxatin sales increased 8.3% at CER (to 70 million) and 6.7% at CER (to 44 million), respectively, with growth driven by China. First-quarter Zaltrap sales increased 43.8% at CER to 22 million, driven by Japan.

In the first quarter, global Diabetes sales decreased at CER 10.0% to 1,356 million, due to lower glargine

(Lantus and Toujeo ) sales in the U.S. First-quarter U.S. Diabetes sales were down 26.6% at CER to 534 million, reflecting

the previously announced changes in coverage in the Part D business and a continued decline in average U.S. glargine net prices. First-quarter sales in Emerging Markets increased at CER 17.7% to 392 million. First-quarter sales in Europe

decreased 0.9% at CER to 323 million, despite Toujeo growth.

In the first quarter,

glargine (Lantus and Toujeo ) sales decreased 13.5% at CER to 1,108 million. U.S. Sanofi glargine sales were down

28.7% at CER to 498 million, reflecting the aforementioned changes in coverage in Part D and a continued decline in average U.S. glargine net prices. In Europe, glargine sales increased 1.2% at CER to 248 million due to the

Toujeo strong performance, despite biosimilar glargine competition in several European markets.

In the first quarter, Lantus sales were

911 million, down 17.7% at CER. In the U.S., Lantus sales decreased 31.0% at CER to 413 million mainly reflecting lower average net price and the change in coverage in

Sanofi s Part D business.

In Europe, first-quarter Lantus sales were

181 million (down 9.0% at CER) due to biosimilar glargine competition and patients switching to Toujeo . In Emerging Markets, first-quarter Lantus sales were up 8.6% at CER to 248 million.

First-quarter Toujeo sales were 197 million, up 13.8% at CER. In the U.S., first-quarter Toujeo sales were 85 million, down 14.8% at CER

versus the first quarter of 2017. In Europe and Emerging Markets, first-quarter Toujeo sales were 67 million (up 45.7% at CER) and 28 million (versus 13 million in the first quarter of 2017).

Soliqua 100/33 (insulin glargine 100 Units/mL & lixisenatide 33 mcg/mL injection)

was launched in the U.S. in January 2017 and Suliqua was also launched in several European countries in 2017. Soliqua 100/33 / Suliqua sales were 9 million in

the first quarter of 2018.

Amaryl sales were 83 million, up 2.2% at CER in

the first quarter, of which 72 million were generated in Emerging Markets (up 9.7% at CER).

First-quarter Apidra sales increased 1.0% at CER to 91 million. Lower sales in the U.S. (down 17.2% at CER to 21 million) were offset by strong growth in Emerging Markets (up 29.2% at CER to 27

Cardiovascular franchise

Praluent sales (collaboration with Regeneron) increased 55.9% at CER to 49 million, of which 26 million was generated in the U.S. and 19 million in

Europe. This reflected the continued significant payer utilization management restrictions in the U.S. and limited market access in Europe.

Sanofi and Regeneron announced positive data from the ODYSSEY OUTCOMES study. Results showed that Praluent significantly reduced the risk of cardiovascular events in high-risk patients. For

the first time, adding a lipid-lowering therapy to maximally-tolerated statins was associated with a reduction of all-cause mortality(13). Sanofi and Regeneron also announced plans to make Praluent more accessible and

affordable for patients with the greatest health risk and unmet need.

Multaq sales were 79 million (down 9.2% at CER).

Established Rx Products

In the first quarter, Established Rx Products sales decreased 6.4% to 2,320 million. This reflected generic

competition to Renvela /Renagel (sevelamer) in the U.S., which more than offset strong growth in Emerging Markets (up 9.7% at CER to

decreased 0.7% at CER to 391 million in the first quarter, reflecting increased competition in Europe (down 5.1% at CER to 244 million), which offset the growth in Emerging Markets (up 9.2% at CER to 115 million). Biosimilars

are available in the UK, Germany and Italy.

In the first quarter, Plavix sales were up 8.9% at CER to 387 million sustained by strong Emerging Markets performance (up 22.1% at CER to 297 million) driven by China. Sales in Japan were down 37.5% at CER to

37 million, reflecting generic competition.

Renvela /Renagel (sevelamer) sales decreased 54.1% at CER to 101 million, due to generic competition in the U.S. (down 66.2% at CER to 61 million).

Aprovel /Avapro sales decreased 3.1% at CER to 172 million, reflecting lower sales to Sanofi s

partner in Japan which offset the strong performance in China.

CHC sales by geography and category are provided in Appendix 1.